TY - JOUR
T1 - Close monitoring and early intervention
T2 - management principles for cystic fibrosis in Denmark
AU - Qvist, Tavs
AU - Nielsen, Bibi Uhre
AU - Olesen, Hanne Vebert
AU - Mathiesen, Inger Hee Mabuza
AU - Faurholt-Jepsen, Daniel
AU - Katzenstein, Terese L.
AU - Helweg-Larsen, Jannik
AU - Rönsholt, Frederikke
AU - Jeppesen, Majbritt
AU - Olsen, Mette Frahm
AU - Buchvald, Frederik Fouirnaies
AU - Nielsen, Kim Gjerum
AU - Jensen-Fangel, Søren
AU - Pressler, Tania
AU - Skov, Marianne
N1 - Publisher Copyright:
© 2024 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
PY - 2024
Y1 - 2024
N2 - Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.
AB - Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.
KW - benchmarking
KW - clinical practice
KW - guideline
KW - outcome
KW - Standard of care
U2 - 10.1111/apm.13375
DO - 10.1111/apm.13375
M3 - Review
C2 - 38267398
AN - SCOPUS:85183001195
VL - 132
SP - 223
EP - 235
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 4
ER -